{"success":true,"data":{"pressRelease":{"id":"171944","rtpr_id":"nGNXb4f6nW-20261018","ticker":"SYRE","exchange":"NASDAQ","all_tickers":["SYRE"],"title":"Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026","author":"Globe Newswire","published_at":"2026-10-18T13:30:00.094Z","article_body":"WALTHAM, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc.\n(NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing\nnext-generation therapies that elevate the standard in immunology by\ndelivering more complete disease control, greater durability, and a simpler\ntreatment experience for patients, today announced presentations at United\nEuropean Gastroenterology Week (UEGW) 2026 in Barcelona. The presentations\ninclude the first scientific congress presentation of clinical data across all\nthree of Spyre’s IBD antibodies—SPY001 (anti-α4β7), SPY002 (anti-TL1A),\nand SPY003 (anti-IL-23)—which are now being tested as monotherapies and\npairwise combinations in the SKYLINE study, as well as new preclinical data\ndemonstrating additive efficacy of these complementary mechanisms.\n\n“Despite significant advances in the treatment of IBD, many patients still\ndo not achieve or maintain the level of disease control we would like to see,\nunderscoring the need for new approaches that can deliver deeper and more\ndurable responses,” said Silvio Danese, M.D., Ph.D., Professor of\nGastroenterology at Vita-Salute San Raffaele University and Head of the\nGastroenterology and Endoscopy Unit at IRCCS San Raffaele Hospital in Milan,\nand Chair of the SKYLINE trial Steering Committee. “We believe that advanced\ncombination therapy provides a strong probability of enhanced efficacy\ncompared to today’s monotherapies, and Spyre’s approach of combining\noptimized versions of antibodies against proven targets represents one of the\nmost promising pipelines in the field. With clinical proof-of-concept now\ndemonstrated across SPY001, SPY002 and SPY003, we are increasingly excited to\nsee the combination results next year with the potential to raise the\ntherapeutic ceiling for patients with IBD.”\n\nThe poster and presentation will be available for viewing during UEGW, and\ndetails are as follows:\n\nOral Presentation\n\nTitle: Efficacy and Safety of Half-Life Extended Antibodies SPY001, SPY002,\nand SPY003 for Induction Treatment of Moderately to Severely Active Ulcerative\nColitis\nAbstract Session: Hot Topics in IBD\nPresentation Date/Time: Sunday, Oct. 18,15:30-15:40 CEST\nPresentation Location: Room B3\nPresenter: Silvio Danese, M.D., Ph.D., San Raffaele Hospital\n\nModerated Poster\n\nTitle: Anti-α4β7 integrin, anti-TL1A, and anti-IL-23 are efficacious in\nTNBS-induced colitis using humanized mice, and combinations further improve\nefficacy\nPoster Session: New Insights into IBD Biology (II)\nSession Date/Time: Monday, Oct. 19, 16:06-16:12 CEST\nPresentation Location: Hall 7, Poster Stage 2\nPresenter: Andy Spencer, Ph.D., Spyre Therapeutics\n\nFull session details can be accessed via the UEGW program.\n\nAbout Spyre Therapeutics\n\nSpyre Therapeutics is a clinical-stage biotechnology company committed to\ndeveloping next-generation therapies that elevate the standard in immunology\nby delivering more complete disease control, greater durability, and a simpler\ntreatment experience for patients. Spyre's pipeline includes investigational\nextended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F as\nwell as rational combination programs.\n\nFor more information, visit Spyre's website at www.spyre.com.\n\nForward-Looking Statements\nCertain statements in this press release, other than purely historical\ninformation, may constitute \"forward-looking statements\" within the meaning of\nthe federal securities laws, including for purposes of the safe harbor\nprovisions under the United States Private Securities Litigation Reform Act of\n1995, concerning Spyre and other matters. These forward-looking statements\ninclude, but are not limited to, express or implied statements relating to\nSpyre's management team's expectations, hopes, beliefs, intentions or\nstrategies regarding the future including, without limitation, Spyre’s\nability to develop next-generation therapies that elevate the standard in\nimmunology by delivering more complete disease control, greater durability,\nand a simpler treatment experience for patients; the potential of advanced\ncombination therapy to provide enhanced efficacy compared to today’s\nmonotherapies; the potential of combination therapies to raise the therapeutic\nceiling for patients with IBD; and Spyre’s clinical development activities,\nincluding the expected timing and results of the ongoing SKYLINE Phase 2\nplatform trial, including timing of data readouts. In addition, any statements\nthat refer to projections, forecasts or other characterizations of future\nevents or circumstances, including any underlying assumptions, are\nforward-looking statements. The words \"opportunity,\" \"potential,\"\n\"milestones,\" \"pipeline,\" \"can,\" \"goal,\" \"aim,\" \"strategy,\" \"target,\" \"seek,\"\n\"anticipate,\" \"achieve,\" \"believe,\" \"contemplate,\" \"continue,\" \"could,\"\n\"estimate,\" \"expect,\" \"intends,\" \"may,\" \"might,\" \"plan,\" \"possible,\"\n\"predict,\" \"project,\" \"should,\" \"will,\" \"would,\" and similar expressions\n(including the negatives of these terms or variations of them) may identify\nforward-looking statements, but the absence of these words does not mean that\na statement is not forward-looking. These forward-looking statements are based\non current expectations and beliefs concerning future developments and their\npotential effects. There can be no assurance that future developments\naffecting Spyre will be those that have been anticipated. These\nforward-looking statements involve a number of risks, uncertainties (some of\nwhich are beyond Spyre's control) or other assumptions that may cause actual\nresults or performance to be materially different from those expressed or\nimplied by these forward-looking statements. These risks and uncertainties\ninclude, but are not limited, uncertainties and risks arising from regulatory\nfeedback, including potential disagreement by regulatory authorities with the\nCompany’s interpretation of data and the Company’s clinical trials for its\nproduct candidates; the potential for interim data not being delivered within\nexpected time frames or final data not being consistent with or different than\nthe topline or interim data reported for our programs; the potential impact of\nTrump Administration policies and changes in law on our business; and those\nuncertainties and factors described under the heading \"Risk Factors,\" \"Risk\nFactor Summary\" and \"Note about Forward-Looking Statements\" in Spyre's most\nrecent Annual Report on Form 10-K, as supplemented and updated by subsequent\nQuarterly Reports on Form 10-Q and Current Reports on Form 8-K that the\nCompany has filed or will file with the SEC, as well as discussions of\npotential risks, uncertainties, and other important factors included in other\nfilings by Spyre from time to time. Should one or more of these risks or\nuncertainties materialize, or should any of Spyre's assumptions prove\nincorrect, actual results may vary in material respects from those projected\nin these forward-looking statements. Nothing in this press release should be\nregarded as a representation by any person that the forward-looking statements\nset forth therein will be achieved or that any of the contemplated results of\nsuch forward-looking statements will be achieved. You should not place undue\nreliance on forward-looking statements in this press release, which speak only\nas of the date they are made and are qualified in their entirety by reference\nto the cautionary statements herein. Spyre does not undertake or accept any\nduty to make any updates or revisions to any forward-looking statements. This\npress release does not purport to summarize all of the conditions, risks and\nother attributes of an investment in Spyre.\n\nFor Investors:      \nEric McIntyre\nSVP of Finance and Investor Relations\nSpyre Therapeutics\nEric.mcintyre@spyre.com\n\nFor Media:      \nJosie Butler, 1AB\njosie@1abmedia.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/bc26a912-b583-43c6-8423-55a4ba2bf4bd)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXb4f6nW-20261018","title":"Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026","author":"Globe Newswire","ticker":"SYRE","created":"2026-10-18T13:30:00.094Z","tickers":["SYRE"],"exchange":"NASDAQ","article_body":"WALTHAM, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc.\n(NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing\nnext-generation therapies that elevate the standard in immunology by\ndelivering more complete disease control, greater durability, and a simpler\ntreatment experience for patients, today announced presentations at United\nEuropean Gastroenterology Week (UEGW) 2026 in Barcelona. The presentations\ninclude the first scientific congress presentation of clinical data across all\nthree of Spyre’s IBD antibodies—SPY001 (anti-α4β7), SPY002 (anti-TL1A),\nand SPY003 (anti-IL-23)—which are now being tested as monotherapies and\npairwise combinations in the SKYLINE study, as well as new preclinical data\ndemonstrating additive efficacy of these complementary mechanisms.\n\n“Despite significant advances in the treatment of IBD, many patients still\ndo not achieve or maintain the level of disease control we would like to see,\nunderscoring the need for new approaches that can deliver deeper and more\ndurable responses,” said Silvio Danese, M.D., Ph.D., Professor of\nGastroenterology at Vita-Salute San Raffaele University and Head of the\nGastroenterology and Endoscopy Unit at IRCCS San Raffaele Hospital in Milan,\nand Chair of the SKYLINE trial Steering Committee. “We believe that advanced\ncombination therapy provides a strong probability of enhanced efficacy\ncompared to today’s monotherapies, and Spyre’s approach of combining\noptimized versions of antibodies against proven targets represents one of the\nmost promising pipelines in the field. With clinical proof-of-concept now\ndemonstrated across SPY001, SPY002 and SPY003, we are increasingly excited to\nsee the combination results next year with the potential to raise the\ntherapeutic ceiling for patients with IBD.”\n\nThe poster and presentation will be available for viewing during UEGW, and\ndetails are as follows:\n\nOral Presentation\n\nTitle: Efficacy and Safety of Half-Life Extended Antibodies SPY001, SPY002,\nand SPY003 for Induction Treatment of Moderately to Severely Active Ulcerative\nColitis\nAbstract Session: Hot Topics in IBD\nPresentation Date/Time: Sunday, Oct. 18,15:30-15:40 CEST\nPresentation Location: Room B3\nPresenter: Silvio Danese, M.D., Ph.D., San Raffaele Hospital\n\nModerated Poster\n\nTitle: Anti-α4β7 integrin, anti-TL1A, and anti-IL-23 are efficacious in\nTNBS-induced colitis using humanized mice, and combinations further improve\nefficacy\nPoster Session: New Insights into IBD Biology (II)\nSession Date/Time: Monday, Oct. 19, 16:06-16:12 CEST\nPresentation Location: Hall 7, Poster Stage 2\nPresenter: Andy Spencer, Ph.D., Spyre Therapeutics\n\nFull session details can be accessed via the UEGW program.\n\nAbout Spyre Therapeutics\n\nSpyre Therapeutics is a clinical-stage biotechnology company committed to\ndeveloping next-generation therapies that elevate the standard in immunology\nby delivering more complete disease control, greater durability, and a simpler\ntreatment experience for patients. Spyre's pipeline includes investigational\nextended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F as\nwell as rational combination programs.\n\nFor more information, visit Spyre's website at www.spyre.com.\n\nForward-Looking Statements\nCertain statements in this press release, other than purely historical\ninformation, may constitute \"forward-looking statements\" within the meaning of\nthe federal securities laws, including for purposes of the safe harbor\nprovisions under the United States Private Securities Litigation Reform Act of\n1995, concerning Spyre and other matters. These forward-looking statements\ninclude, but are not limited to, express or implied statements relating to\nSpyre's management team's expectations, hopes, beliefs, intentions or\nstrategies regarding the future including, without limitation, Spyre’s\nability to develop next-generation therapies that elevate the standard in\nimmunology by delivering more complete disease control, greater durability,\nand a simpler treatment experience for patients; the potential of advanced\ncombination therapy to provide enhanced efficacy compared to today’s\nmonotherapies; the potential of combination therapies to raise the therapeutic\nceiling for patients with IBD; and Spyre’s clinical development activities,\nincluding the expected timing and results of the ongoing SKYLINE Phase 2\nplatform trial, including timing of data readouts. In addition, any statements\nthat refer to projections, forecasts or other characterizations of future\nevents or circumstances, including any underlying assumptions, are\nforward-looking statements. The words \"opportunity,\" \"potential,\"\n\"milestones,\" \"pipeline,\" \"can,\" \"goal,\" \"aim,\" \"strategy,\" \"target,\" \"seek,\"\n\"anticipate,\" \"achieve,\" \"believe,\" \"contemplate,\" \"continue,\" \"could,\"\n\"estimate,\" \"expect,\" \"intends,\" \"may,\" \"might,\" \"plan,\" \"possible,\"\n\"predict,\" \"project,\" \"should,\" \"will,\" \"would,\" and similar expressions\n(including the negatives of these terms or variations of them) may identify\nforward-looking statements, but the absence of these words does not mean that\na statement is not forward-looking. These forward-looking statements are based\non current expectations and beliefs concerning future developments and their\npotential effects. There can be no assurance that future developments\naffecting Spyre will be those that have been anticipated. These\nforward-looking statements involve a number of risks, uncertainties (some of\nwhich are beyond Spyre's control) or other assumptions that may cause actual\nresults or performance to be materially different from those expressed or\nimplied by these forward-looking statements. These risks and uncertainties\ninclude, but are not limited, uncertainties and risks arising from regulatory\nfeedback, including potential disagreement by regulatory authorities with the\nCompany’s interpretation of data and the Company’s clinical trials for its\nproduct candidates; the potential for interim data not being delivered within\nexpected time frames or final data not being consistent with or different than\nthe topline or interim data reported for our programs; the potential impact of\nTrump Administration policies and changes in law on our business; and those\nuncertainties and factors described under the heading \"Risk Factors,\" \"Risk\nFactor Summary\" and \"Note about Forward-Looking Statements\" in Spyre's most\nrecent Annual Report on Form 10-K, as supplemented and updated by subsequent\nQuarterly Reports on Form 10-Q and Current Reports on Form 8-K that the\nCompany has filed or will file with the SEC, as well as discussions of\npotential risks, uncertainties, and other important factors included in other\nfilings by Spyre from time to time. Should one or more of these risks or\nuncertainties materialize, or should any of Spyre's assumptions prove\nincorrect, actual results may vary in material respects from those projected\nin these forward-looking statements. Nothing in this press release should be\nregarded as a representation by any person that the forward-looking statements\nset forth therein will be achieved or that any of the contemplated results of\nsuch forward-looking statements will be achieved. You should not place undue\nreliance on forward-looking statements in this press release, which speak only\nas of the date they are made and are qualified in their entirety by reference\nto the cautionary statements herein. Spyre does not undertake or accept any\nduty to make any updates or revisions to any forward-looking statements. This\npress release does not purport to summarize all of the conditions, risks and\nother attributes of an investment in Spyre.\n\nFor Investors:      \nEric McIntyre\nSVP of Finance and Investor Relations\nSpyre Therapeutics\nEric.mcintyre@spyre.com\n\nFor Media:      \nJosie Butler, 1AB\njosie@1abmedia.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/bc26a912-b583-43c6-8423-55a4ba2bf4bd)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-18T13:30:00.143973309Z","server_sent_at_ms":1792330200143},"received_at":"2026-10-18T13:30:00.209Z","source_url":null},"analysis":{"id":"160092","press_release_id":"171944","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["key combination data readout not expected until next year; no quantitative efficacy figures included in this release"],"eventType":"clinical_trial","narrative":"Spyre Therapeutics will present the first congress data covering all three of its IBD antibodies — SPY001 (anti-α4β7), SPY002 (anti-TL1A), and SPY003 (anti-IL-23) — at United European Gastroenterology Week 2026 in Barcelona.\n\nThe data come from the SKYLINE Phase 2 platform trial, where the antibodies are being tested as monotherapies and pairwise combinations; new preclinical data show additive efficacy of the combined mechanisms.\n\nSteering Committee Chair Silvio Danese says clinical proof-of-concept is now demonstrated across all three antibodies, with combination results expected next year — the key catalyst for raising the therapeutic ceiling in IBD.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"First public congress look at Spyre's three-antibody IBD franchise; set watch on 2026 combination readout as the real binary."},"keyFigures":{"drugName":"SPY001, SPY002, SPY003","phaseOfTrial":"Phase 2","customDimensions":{"study_name":"SKYLINE","antibody_count":3,"combo_data_timing":"next year"}},"quotedText":"We believe that advanced combination therapy provides a strong probability of enhanced efficacy compared to today’s monotherapies, and Spyre’s approach of combining optimized versions of antibodies against proven targets represents one of the most promising pipelines in the field.","namedEntities":{"people":[{"name":"Silvio Danese","role":"Chair of the SKYLINE trial Steering Committee; Professor of Gastroenterology, Vita-Salute San Raffaele University"},{"name":"Andy Spencer","role":"Spyre Therapeutics (preclinical poster presenter)"},{"name":"Eric McIntyre","role":"SVP of Finance and Investor Relations"}],"products":["SPY001 (anti-α4β7)","SPY002 (anti-TL1A)","SPY003 (anti-IL-23)"],"companies":[{"name":"Spyre Therapeutics, Inc.","ticker":"SYRE","relationship":"filer"},{"name":"IRCCS San Raffaele Hospital","relationship":"investigator site"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Congress data presentations of ongoing Phase 2 SKYLINE program data with clinical proof-of-concept claimed across three IBD antibodies; no new trial results, endpoints, or regulatory milestones disclosed — a data-visibility event, not a binary readout."},"tickerRelevance":{"others":[],"primary":"SYRE"},"globalImportance":25,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap biotech","eventGravity":"congress data presentations, no new readout","eventGravityDetail":"proof-of-concept framing, catalyst deferred to next year","retailFavoriteBoost":"moderate biotech investor interest"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Spyre Therapeutics will present the first congress data covering all three of its IBD antibodies — SPY001 (anti-α4β7), SPY002 (anti-TL1A), and SPY003 (anti-IL-23) — at United European Gastroenterology Week 2026 in Barcelona.\n\nThe data come from the SKYLINE Phase 2 platform trial, where the antibodies are being tested as monotherapies and pairwise combinations; new preclinical data show additive efficacy of the combined mechanisms.\n\nSteering Committee Chair Silvio Danese says clinical proof-of-concept is now demonstrated across all three antibodies, with combination results expected next year — the key catalyst for raising the therapeutic ceiling in IBD.","key_figures":{"drugName":"SPY001, SPY002, SPY003","phaseOfTrial":"Phase 2","customDimensions":{"study_name":"SKYLINE","antibody_count":3,"combo_data_timing":"next year"}},"named_entities":{"people":[{"name":"Silvio Danese","role":"Chair of the SKYLINE trial Steering Committee; Professor of Gastroenterology, Vita-Salute San Raffaele University"},{"name":"Andy Spencer","role":"Spyre Therapeutics (preclinical poster presenter)"},{"name":"Eric McIntyre","role":"SVP of Finance and Investor Relations"}],"products":["SPY001 (anti-α4β7)","SPY002 (anti-TL1A)","SPY003 (anti-IL-23)"],"companies":[{"name":"Spyre Therapeutics, Inc.","ticker":"SYRE","relationship":"filer"},{"name":"IRCCS San Raffaele Hospital","relationship":"investigator site"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-18T13:30:05.463Z","global_importance":25,"audience_relevance":25,"importance_components":{"tickerTier":"small-cap biotech","eventGravity":"congress data presentations, no new readout","eventGravityDetail":"proof-of-concept framing, catalyst deferred to next year","retailFavoriteBoost":"moderate biotech investor interest"}},"durationMs":5230,"modelName":"glm-5.3-flashx"}}